Enabling you to identify and mitigate the intrinsic risk in your operations, supply chains and business processes.
Evaluating how your products and services meet and exceed quality, safety, sustainability and performance standards.
Validating the specifications, value and safety of your raw materials, products and assets.
Meeting clients’ global demand for clinical development support
Manchester, United Kingdom – Intertek, the leading quality solutions provider to industries worldwide, today announced its plans to open a new European immunochemistry laboratory for bioanalytical support of clients’ clinical and pre-clinical immunogenicity and pharmacokinetic (PK) studies for biologic medicines.
Operated from the Manchester biologics centre of excellence, this new 10,000 ft² facility with temperature and humidity control will deliver world class scientific support to clients focused on clinical and pre-clinical development of biologic medicines such as monoclonal antibodies, proteins and biosimilars.
The expansion not only builds on the existing service at Manchester, but gives clients access to large molecule bioanalytical support in both Europe and the USA. This facility mirrors the Intertek San Diego immunochemistry facility, which was expanded last year, and will provide global clients access to specific methods operated from both facilities, requiring no further local validation.
This expansion reflects the fast growth of the global biopharmaceutical market over the past decade and the predicted further growth in particular in the development of novel therapeutic antibodies. Accompanying this growth in the sector is also the fast growth of demand for outsourcing services, including bioanalytical support.
These biologic medicines provide a new class of therapeutics for those diseases previously treated with small-molecule drugs, as well as a type of novel treatment for those previously untreatable diseases.
“Expanding our large molecule bioanalytical capability in Europe enables us to be more responsive to the needs of our clients who increasingly seek global service support from regional locations” said Chetan Parmar, Senior Vice President of Intertek Life Sciences.
Ashleigh Wake, Biopharmaceutical Services Leader, UK, said “This expansion will help meet many challenges that our clients face throughout increasingly complex biologic drug development. The clinical and pre-clinical bioassay capability complements our strengths in protein analysis and biological activity testing.”
Intertek has been providing Good Laboratory Practice (GLP) compliant bioanalytical services to global pharmaceutical clients supporting their preclinical and clinical studies and immunogenicity assessment for over 20 years. Intertek also provides pharmaceutical development and manufacturing support services spanning analysis, bioanalysis, formulation development, regulatory consultancy, auditing and supply chain management solutions from its network of offices and regulatory laboratories across the globe.
Dr Lorna Kettle, Marketing Manager, Intertek Pharmaceutical Services
Tel.:+44 161 721 1476, Email: email@example.com
Intertek is a leading quality solutions provider to industries worldwide. From auditing and inspection, to testing, training, advisory, quality assurance and certification, Intertek adds value for its customers by helping improve the quality and safety of their products, assets and processes. With a network of more than 1,000 laboratories and offices and over 38,000 people in more than 100 countries, Intertek supports companies’ success in the global marketplace, by helping customers to meet end users’ expectations for safety, sustainability, performance, integrity and desirability in virtually any market worldwide. Visit www.intertek.com.